Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables (2023 - 2025)

Historic Receivables for ARS Pharmaceuticals (SPRY) over the last 3 years, with Q3 2025 value amounting to $40.7 million.

  • ARS Pharmaceuticals' Receivables rose 430216.22% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year increase of 430216.22%. This contributed to the annual value of $9.4 million for FY2024, which is 134279.14% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Receivables is $40.7 million, which was up 430216.22% from $27.2 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Receivables registered a high of $40.7 million during Q3 2025, and its lowest value of $652000.0 during Q4 2023.
  • For the 3-year period, ARS Pharmaceuticals' Receivables averaged around $14.9 million, with its median value being $9.8 million (2024).
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 134279.14% in 2024, then surged by 430216.22% in 2025.
  • ARS Pharmaceuticals' Receivables (Quarter) stood at $652000.0 in 2023, then soared by 1342.79% to $9.4 million in 2024, then skyrocketed by 332.87% to $40.7 million in 2025.
  • Its Receivables stands at $40.7 million for Q3 2025, versus $27.2 million for Q2 2025 and $10.3 million for Q1 2025.